1 Inference of causal relationships based on the genetics of cardiometabolic traits and 2 conditions unique to females in >50,000 participants

3

Brenda Xiao¹, Digna R. Velez Edwards², Anastasia Lucas³, Theodore Drivas³, Kathryn 4

- Gray⁴, Brendan Keating⁵, Chunhua Weng⁶, Gail P. Jarvik⁷, Hakon Hakonarson⁸, Leah 5
- 6 Kottyan⁹, Noemie Elhadad⁶, Regeneron Genetics Center, Wei-Qi Wei¹⁰, Yuan Luo¹¹,
- 7 Dokyoon Kim¹², Marylyn Ritchie³, Shefali Setia Verma¹³*
- 8 1. University of Pennsylvania
- 9 2. Division of Quantitative Sciences, Department of Obstetrics and Gynecology,
- 10 Vanderbilt University Medical Center
- 11 3. Department of Genetics, University of Pennsylvania
- 12 4. Brigham and Women's Hospital Department of Obstetrics and Gynecology
- 5. Department of Surgery, University of Pennsylvania 13
- 14 6. Department of Biomedical Informatics, Columbia University
- 7. Departments of Medicine (Medical Genetics) and Genome Sciences, University of 15
- 16 Washington Medical Center
- 17 8. Center for Applied Genomics, Children's Hospital of Philadelphia
- 18 9. Center for Autoimmune Genomics and Etiology and Division of Allergy &
- 19 Immunology, Cincinnati Children's Hospital Medical Center, Department of 20 Pediatrics, University of Cincinnati
- 21 10. Department of Biomedical Informatics, Vanderbilt University Medical Center
- 22 11. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern 23 University
- 24 12. Department of Biostatistics and Epidemiology, University of Pennsylvania
- 25 13. Department of Pathology and Laboratory Medicine, University of Pennsylvania NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
- 26

27 Abstract:

28

Background: Cardiometabolic diseases are highly comorbid and associated with poor health outcomes. However, the investigation of the relationship between the genetic predisposition to cardiometabolic diseases with the risk of conditions unique to females such as breast cancer, endometriosis and pregnancy-related complications is highly understudied. This study aimed to estimate the cross-trait genetic overlap and influence of genetic burden of cardiometabolic traits on health conditions unique to females.

35 Methods: We obtained data for female participants in the Penn Medicine BioBank (PMBB; 36 21,837 samples) and the electronic MEdical Records and GEnomics (eMERGE; 49,171 37 samples) network. We examined the relationship between four cardiometabolic phenotypes 38 (body mass index (BMI), coronary artery disease (CAD), type 2 diabetes (T2D) and 39 hypertension (through blood pressure measurements)) and 23 female health conditions by 40 performing four analyses: 1) Cross-trait genetic correlation analyses to compare genetic 41 architecture. 2) Polygenic risk scores (PRS)-based association tests to characterize shared 42 genetic effects on disease risk. 3) Mendelian randomization (MR) for significant associations 43 to assess cross-trait causal relationships. 4) Chronology analyses to visualize the timeline of 44 events unique to groups of females with high and low genetic burden for cardiometabolic 45 traits and highlight the disease prevalence in risk groups by age.

Results: We observed high genetic correlation among cardiometabolic and female health conditions. PRS meta-analysis identified 29 significant associations reflecting potential shared biology among common cardiometabolic phenotypes and female health conditions. Significant associations include PRS_{BMI} with endometrial cancer and polycystic ovarian syndrome (PCOS), PRS_{CAD} with breast cancer, and the PRS_{T2D} with gestational diabetes and PCOS. Mendelian randomization provided additional evidence of independent causal effects between T2D and gestational diabetes and CAD and with breast cancer. Our results reflected

inverse association between PRS_{CAD} and breast cancer. Lastly, as visualized from chronology
analyses, individuals with high PRS are also more likely to develop conditions such as PCOS
and gestational hypertension at earlier ages. **Conclusions:** Polygenic susceptibility to cardiometabolic traits is associated with conditions

57 unique to females. Several of these associations are likely to result from the complex 58 pathophysiology of cardiometabolic risk, and others may reflect potential pleiotropic effects 59 that go beyond cardiometabolic health in females.

60 Introduction:

61 Cardiometabolic diseases such as coronary artery disease (CAD), obesity, hypertension, and type 2 diabetes (T2D) are profoundly prevalent and among the leading 62 63 causes of death in the world^{5,6,7}. Cardiometabolic conditions are highly comorbid and 64 considered as risk factors for sequelae of many diseases, such as depression, anxiety, chronic obstructive pulmonary disease (COPD), and cancer, to name a few^{8,9}. These conditions 65 66 affect female individuals disproportionately because they are also linked to disorders of the reproductive system and adverse outcomes of pregnancy and childbirth such as preeclampsia, 67 68 gestational diabetes, stillbirth, and pregnancy loss^{10,11}. Many studies suggest that the 69 pathophysiology of cardiometabolic diseases affects males and females differently¹⁴. There 70 are multiple shreds of evidence supporting the relationship between female health conditions 71 and cardiometabolic diseases. For instance, people who develop preeclampsia during pregnancy are more likely to develop cardiovascular diseases and hypertension after 72 pregnancy^{15,16}. Additionally, obesity and polycystic ovarian syndrome (PCOS) are closely 73 74 linked conditions, and people with PCOS are at high risk of developing T2D¹⁷⁻¹⁹. People with 75 endometriosis are also at high risk for developing oncological cancers and cardiovascular diseases such as myocardial infarction and ischemic heart disease^{20,21}. However, the 76 relationship between female health and cardiometabolic phenotypes, particularly the potential 77 78 for any shared genetic burden between them, is still highly understudied. The investigation of 79 shared genetic burden could lead to identifying obesity and cardiometabolic cluster-related 80 risk factors associated with female health conditions to modify standard screening practices 81 in people at high risk for many diseases.

Genome-wide association studies (GWAS) in the past couple of decades have exposed common cross-trait connections. Disease traits such as type 2 diabetes, obesity, sleep apnea, hypertension, Alzheimer's diseases, and many cancer types have been shown to

share genetic etiology¹⁻⁴. GWAS have identified >1000 loci with a likely impact on 85 86 cardiometabolic phenotypes, but the effect size of any single variant is generally tiny. Many 87 methods have identified relationships between different phenotypes and traits by calculating 88 their genetic correlation from GWAS effect sizes. In addition, to more accurately estimate an 89 individual's overall risk for disease, researchers have used GWAS to calculate polygenic risk 90 scores (PRS), which sum up the effect of common single nucleotide polymorphisms (SNPs) 91 throughout the genome into a single score of overall genetic burden for a phenotype²⁷. PRS 92 have been shown to predict the risk of many cardiometabolic diseases and its 93 comorbidities^{28,29}.

94 Our approach to investigating the impact of genetic burden of cardiometabolic traits 95 in female health conditions is to measure the genetic correlation and association of 96 cardiometabolic PRS with EHR-derived phenotypes. Many prior studies have successfully 97 used PRS as the genetic risk factor for identifying links between overall genetic risk for one 98 phenotype to other phenotypes^{31,32}. PRS-based association tests make fewer assumptions and 99 have the benefit that they are based on unvarying risk factors (i.e., inherited genetic burden). 100 We hypothesize that the genetic burden for cardiometabolic phenotypes could further explain 101 the phenotypic variance in health conditions unique to females. This present study obtained 102 genotyped data and a wide range of female health conditions from the Penn Medicine 103 BioBank (PMBB) and the Electronic Medical Records and Genomics (eMERGE) Network. 104 We measured pairwise genetic correlation between cardiometabolic phenotypes and female 105 health conditions to identify the strength of shared genetic factors. The association of PRS 106 with multiple selected phenotypes is further used to estimate the significance of associations 107 between cardiometabolic genetic burden and female health conditions. We additionally 108 evaluated the causal relationship between significant associations by using Mendelian 109 randomization (MR) approaches. Lastly, electronic health record (EHR) data provides the

opportunity to map female health by considering the disease prevalence by age. We generated a chronological map of diseases in participants in high and low PRS groups to understand the prevalence of diseases in the two risk groups at different ages.

113 Methods: The authors have individual level access to genotype and medical record data 114 from the Penn Medicine BioBank and the Electronic Medical Records and Genomics 115 network datasets.

116 Study Populations

117 Penn Medicine BioBank: The Penn Medicine BioBank (PMBB) is a University of 118 Pennsylvania academic biobank which recruits patient-participants from the University of Pennsylvania Health System around the greater Philadelphia area in the United States. 119 120 PMBB links an individual's genotype data with detailed electronic health record (EHR) information. Currently, PMBB consists of genome-wide genotyped and whole-exome 121 122 sequenced data on ~45,000 samples. PMBB is a diverse cohort, with over 25% of 123 participants of African ancestry. PMBB genotyped data is imputed to TOPMED Reference 124 panel using the Michigan Imputation server. We included 21,837 female participants from 125 PMBB in this study (Table 1). The stratified analyses in this study only included participants 126 of European and African ancestry and excluded those from Asian and Hispanic ancestries 127 due to the limiting sample size.

128

eMERGE: The Electronic Medical Records and Genomics (eMERGE) Network is a nationwide consortium containing individuals with genome-wide genotyped data linked to EHRs from several health systems across the United States, with most participants from the Geisinger Health System and Vanderbilt University. eMERGE data is imputed to Haplotype Reference Consortium panel using Michigan Imputation Server. Like PMBB, the eMERGE

134 cohort is diverse across ancestries and ages. This study was performed on 49,171 female
135 patients in eMERGE born after 2001 (Table 1).

136 Genome-wide association studies for cardiometabolic phenotypes

Most genetic correlation and PRS calculation methods require effect sizes of variants on the phenotypes determined through large GWAS. Given the diverse nature of our study population, we obtained the largest publicly available multi-ancestry GWAS summary statistics for six cardiometabolic phenotypes: obesity (measured through body mass index (BMI), CAD, hypertension (measured through diastolic blood pressure (DBP), systolic blood pressure (SBP), and pulse pressure (PP)), and T2D. The summary statistics used for each phenotype and its respective study is referenced in Table 2.

144

145 Genome-wide association for female health conditions

Large multi-ancestry GWAS are not available for most female health conditions evaluated in this study. Thus, we used PLINK version 1.90 to conduct GWAS for the female health conditions in PMBB and eMERGE datasets³³. We filtered the variants in the PMBB imputed datasets to include only those with imputation quality $R^2 > 0.3$ and minor allele frequency > 0.01. We then meta-analyzed the GWAS from our two cohorts in PLINK.

151 Genetic correlation calculation

We calculated pairwise genetic correlation between cardiometabolic phenotypes and female health conditions using LD score regression (LDSC), with the large publicly available cardiometabolic GWAS and the meta-analyzed GWAS for female health conditions from PMBB and eMERGE as input GWAS³⁴. LDSC accounts for linkage disequilibrium (LD) among SNPs by using an external reference panel that should also match the ancestry

distribution of the GWAS. We generated a multi-ancestry LD reference panel using the
HapMap3 SNPs (~1M common variants) from the entire 1000 Genomes population.

159 Polygenic Risk Scores (PRS)

160 PRS calculated using GWAS performed in one ancestry group tend to perform poorly 161 in individuals from different ancestries^{27,35,36}. To accurately calculate a PRS for our diverse target datasets (PMBB and eMERGE), we calculated a PRS for the six different 162 163 cardiometabolic phenotypes using the large publicly available multi-ancestry GWAS used in 164 the genetic correlation analyses. Weights for each SNP included in the PRS were calculated using PRS-CS (version from Apr 24, 2020)³⁸. Like LDSC, PRS-CS requires a reference 165 166 panel that matches the ancestry distribution of the target dataset, and we generated a similar 167 multi-ancestry LD reference panel using the HapMap SNPs from 1000 Genomes. We used 168 PLINK(v1.90) to identify LD blocks and calculate the LD between the SNPs in each block. 169 For PRS-CS, the global shrinkage parameter phi was fixed to 0.01, and default values were 170 selected for all other parameters. PRS was then calculated using these weights through 171 PLINK. Only the SNPs in the target dataset, summary statistics, and LD reference panel were 172 included in the PRS. The number of SNPs used for PRS calculation is listed in Table 2. 173 Scores were then normalized to obtain meaningful beta coefficients.

174 To evaluate the power of PRS, we tested the performance of each PRS on predicting 175 the primary phenotype of the summary statistics. We could not obtain any blood pressure 176 quantitative measurements for participants from eMERGE, and PP and SBP measurements 177 were not curated in PMBB. Therefore, we evaluated the performance of the PRS from blood 178 pressure traits (SP, DBP, PP) in eMERGE on hypertension case-control phenotype and in 179 PMBB by predicting DBP or hypertension (for SBP and PP) as outcomes. We constructed 180 logistic regression models for binary phenotypes (CAD, T2D, and hypertension), and 181 evaluated PRS performance based on the area under the receiver-operator curve (AUC) using

R's *pROC* package. Similarly, we constructed linear regression models for continuous phenotypes (BMI and DBP) and evaluated them based on the R² using R's *glm* function. The regression models used birth year and the first five principal components (PCs) as covariates.
We tested PRS performance in all individuals as well as in only European and African ancestry individuals.

187 Phenotype data

188 Cases and controls for each phenotype were defined using International Classification 189 of Disease (ICD) diagnosis codes. Participants were coded as cases for a phenotype if they 190 had at least one occurrence of the corresponding ICD codes. For pregnancy-related 191 phenotypes, participants were only considered as controls for a phenotype if they had at least 192 one occurrence of a pregnancy-related ICD code and no occurrences of codes for certain 193 complications during pregnancy (such as miscarriage) or any of the case ICD codes. 194 Participants were counted as controls for cardiometabolic and all other female health 195 conditions if they did not have any of the case ICD codes. The complete list of all ICD codes 196 used to include or exclude participants as cases and controls can be found in Supplementary 197 Table 1. Using these definitions, we determined the sample size for each phenotype in 198 eMERGE and PMBB (Table 1).

199 **PRS** association analyses

We tested the association of each cardiometabolic PRS and female health conditions by fitting separate logistic regression models, adjusting the models by birth year and the first five PCs. We conducted this analysis in all participants as well as ancestry-stratified analyses for individuals of European and African ancestry. To account for biases from multiple hypothesis testing, we determined if these associations passed an FDR-significance threshold of 0.05, using the number of female health conditions (23) as the number of hypotheses

tested. The logistic regressions were performed using R's *glm* function, and results from PMBB and eMERGE were combined using the *rma* function from the *metafor* R package under the restricted maximum-likelihood estimator model³⁷. We used PheWAS-View to visualize our results³⁹. We then created prevalence plots for each significant association. Participants were divided into quintiles based on their PRS, and the percentage of cases for the most significant female health conditions was calculated at each quintile.

212 Mendelian Randomization

213 To identify potential evidence of causality between cardiometabolic phenotypes and 214 female health conditions, we performed one-sample Mendelian randomization (MR) for 29 215 significant associations from PRS analyses using the *ivreg* function from the *ivpack* R package. Cardiometabolic PRS were used as genetic instruments in the one-sample MR, with 216 217 birth year and the first five PCs included as covariates. Results were combined through meta-218 analysis using the *metafor* R package as done in the PRS meta-analysis. Since the low sample 219 size for some of the female health conditions could limit the power of our analyses, we also 220 performed two-sample MR for the same associations using the inverse variance weighted (IVW) method in the *twoSampleMR* package in R⁴⁰. MR sensitivity analyses were conducted 221 222 using the weighted median and the MR Egger methods through the same package. Genetic 223 instruments for cardiometabolic phenotypes in the two-sample MR were defined as genome-224 wide significant SNPs in the GWAS summary statistics used to calculate the PRS. SNPs 225 were LD pruned according to LD patterns in the 1000 Genomes HapMap SNPs, and the 226 representative SNPs were included in the analysis. Matching genetic instruments for female 227 health conditions were obtained from publicly available GWAS available through the 228 twoSampleMR package (Supplementary Table 2).

230 Chronology Analyses

231 We divided participants into high-risk and low-risk groups according to each 232 cardiometabolic PRS. High PRS was defined as the top quintile (PRS > 80 percentile), and 233 low PRS was defined as the bottom quintile (PRS < 20 percentile). We obtained the age at 234 the first occurrence of each female health condition according to the ICD record. For 235 pregnancy-related conditions, participants were split into three age groups: <25, 25-40, and 236 40-55. We excluded participants who were over 55 at the first occurrence of pregnancy-237 related conditions due to low sample sizes and potential errors in diagnosis coding. For all 238 other conditions, participants were split into five different age groups: <25, 25-40, 40-55, 55-239 70, and >70. We examined the combined case prevalence in PMBB and eMERGE for female 240 health conditions in high and low PRS groups across all age groups.

241

242 **Results:**

243 Genetic correlation among cardiometabolic phenotypes and female health conditions

244 The six cardiometabolic phenotypes were significantly correlated with six different 245 female health conditions for a total of 13 statistically significant correlations (Figure 1A). 246 BMI was significantly correlated with breast cancer (Rg=-0.179, p=0.011) and PCOS 247 $(R_g=0.4, p=0.007)$, CAD with breast cancer $(R_g=-0.199, p=0.011)$, PCOS $(R_g=0.216, p=0.017)$ p=0.04), and postpartum depression ($R_g=0.204$, p=0.025), PP with gestational hypertension 248 249 $(R_g=0.481, p=0.0025)$, SBP with breast cancer $(R_g=-0.153, p=0.041)$ and gestational hypertension ($R_g=0.523$, p=0.0017), and T2D with breast cancer ($R_g=-0.196$, p=0.0001), 250 251 excessive fetal growth (Rg=0.126, p=0.044), gestational diabetes (Rg=0.529, p=0.011), 252 gestational hypertension (R_g =0.237, p=0.028), and PCOS (R_g =0.316, p=0.0093).

253 **PRS performance on primary phenotype**

254 We calculated a PRS for six cardiometabolic phenotypes for individuals in PMBB 255 and eMERGE and checked the distribution of the raw and normalized PRS (Supplementary 256 Figures 1-6). The full model for all PRS generally performed well in predicting the primary 257 phenotype across ancestry groups (Table 3). PRS was significantly (p < 0.05) associated with 258 the primary phenotype for all cardiometabolic phenotypes. The covariate only model (null 259 model) generally performed better in African ancestry individuals than in European individuals, but the PRS only model generally performed better in European ancestry 260 261 individuals. We calculated the difference between the full and null models for all cardiometabolic PRS in PMBB and eMERGE and found that the PRS improved predictive 262 263 performance significantly more for European ancestry participants than for African ancestry 264 participants (p = 0.000488, Wilcox signed rank test). As such, the cardiometabolic PRS were 265 more accurate in European ancestry individuals but still significantly improved predictive 266 performance in African ancestry individuals.

267 Association of cardiometabolic PRS association and female health conditions

268 We detected numerous associations between cardiometabolic PRS and female health conditions in the meta-analyzed results (Figure 1B-D). 29 associations were statistically 269 significant after correcting for multiple hypothesis burden through FDR significance (Table 270 271 4). Most of these associations were also significantly associated in both PMBB and eMERGE 272 separately (Supplementary Figures 7-12). In the meta-analysis, for all and European ancestry 273 individuals, the PRS_{BMI} was significantly associated with endometrial cancer (beta_{all}=0.24, 274 $se_{all}=0.046$, $p_{all}=9.4x10^{-8}$; beta_{eur}=0.28, $se_{eur}=0.087$, $p_{eur}=0.0015$), gestational diabetes (beta_{all}=0.23, se_{all}=0.051, p_{all} =6x10⁻⁶; beta_{eur}=0.28, se_{eur}=0.062, p_{eur}=8.7x10⁻⁶), and PCOS 275 276 $((beta_{all}=0.27, se_{all}=0.039, p_{all}=2.4 \times 10^{-12}; beta_{eur}=0.29, se_{eur}=0.045 p_{eur}=6.8 \times 10^{-11}).$ The

277 PRS_{BMI} was also significantly associated with breast cancer in all individuals (beta_{all}=-0.071, 278 se_{all}=0.022, p_{all}=0.0016). These results suggest that an increased genetic burden for obesity 279 and high BMI also increases the risk for endometrial cancer, gestational diabetes, and PCOS 280 but decreases the risk for breast cancer. The PRS_{CAD} was also significantly associated with 281 breast cancer for all and European ancestry individuals (beta_{all}=-0.072, se_{all}=0.015, p_{all}=1x10⁻ 282 ⁶; beta_{eur}=-0.07, se_{all}=0.017, p_{eur}= 3.1×10^{-5}). This highly significant negative association suggests that individuals, particularly those of European ancestry, with high PRS_{CAD} are at 283 284 relatively lower risk for breast cancer compared to individuals with low PRS_{CAD}. The PRS_{T2D} 285 was also significantly associated with gestational diabetes in all and European ancestry 286 individuals (beta_{all}=0.58, se_{all}=0.063, $p_{all}=1.2 \times 10^{-20}$; beta_{eur}=0.68, se_{eur}=0.076, $p_{eur}=3.9 \times 10^{-19}$) 287 and with PCOS in all, European ancestry, and African ancestry individuals (beta_{all}=0.22, 288 seall=0.043, pall=1.9x10⁻⁷; betaeur=0.21, seeur=0.049, peur=1.6x10⁻⁵; betaafr=0.32, seafr=0.1, 289 p_{afr}=0.0021). The link between T2D and these female related phenotypes is well known, and 290 our results support a potential genetic basis linking these phenotypes^{18,19}. Among all and 291 European ancestry individuals, the PRS_{T2D} was also significantly associated with gestational 292 hypertension (beta_{all}=0.18, se_{all}=0.064, p_{all}=0.0041; beta_{eur}=0.18, se_{eur}=0.067, p_{eur}=0.008) and 293 breast cancer (beta_{all}=-0.073, se_{all}=0.021, p_{all}=0.00066; beta_{eur}=-0.079, se_{eur}=0.026, 294 peur=0.0027).

The three-blood pressure traits PRS (PRS_{DBP}, PRS_{SBP}, and PRS_{PP}) showed varying significant associations with gestational hypertension and preeclampsia in the PMBB and eMERGE meta-analysis. There was no sign of association between the PRS_{DBP} and these phenotypes in the meta-analysis. However, the PRS_{DBP} was significantly associated with gestational hypertension in PMBB all and African ancestry individuals ($p=1x10^{-05}$, 0.00041) and nominally associated (p<0.01) with preeclampsia in African ancestry participants (p=0.0063). The PRS_{PP} was significantly associated with gestational hypertension for all and

European ancestry participants (beta_{all}=0.22, se_{all}=0.044, p_{all}=8.5x10⁻⁷; beta_{eur}=0.24, se_{eur}=0.056, p_{eur}=2.5x10⁻⁵) and with preeclampsia for all participants (beta_{all}=0.2, se_{all}=0.058, p_{all}=0.00076). The PRS_{SBP} was significantly associated with gestational hypertension and preeclampsia in all, European ancestry, and African ancestry individuals (Gestational hypertension: beta_{all}=0.33, se_{all}=0.083, p_{all}=5.6x10⁻⁵; beta_{eur}=0.31, se_{all}=0.066, p_{eur}=3.6x10⁻⁶; beta_{afr}=0.4, se_{afr}=0.099, p_{afr}=5.7x10⁻⁵; Preeclampsia: beta_{all}=0.28, se_{all}=0.08, p_{all}=0.00057; beta_{eur}=0.23, se_{eur}=0.071, p_{eur}=0.0013; beta_{afr}=0.36, se_{afr}=0.1, p_{afr}=0.00052).

309 For each FDR-significant association in both PMBB and eMERGE, we looked at the 310 case prevalence of the female health condition per the associated PRS quintile (Figure 2B 311 and Supplementary Figures 13-17). The trends matched the results we obtained from the 312 association analyses across ancestry groups and in both datasets. Distribution of the number 313 of cases increased as the PRS percentile increased for the positive associations in the 314 association analysis, such as PCOS with the PRS_{BMI}. The number of cases for breast cancer 315 decreased when increasing the PRS_{CAD} percentile, matching the inverse association between breast cancer and the PRS_{CAD} (Figure 2B). 316

317

318 Association of PRS_{CAD} and breast cancer

To validate the inverse association between PRS_{CAD} and breast cancer, we examined the genetic correlation between CAD and breast cancer from the UKBB Genetic Correlation Browser (Figure 2A). The genetic correlation between I9_CHD (Major coronary heart disease event) and C50 (Diagnoses-main ICD10: C50 Malignant neoplasm of breast) was significantly negative (R_g =-0.24, p =0.0325).

Additionally, to evaluate the risk of ascertainment biases and the reporting of comorbidities in the EHR, we preformed the associations of CAD PRS with breast cancer in females who are not diagnosed with CAD (n=61,201). In the individuals who were not

327 diagnosed with CAD, we observed slightly less significant association between breast cancer 328 and CAD (beta_{all}=-0.0484, p_{all}=0.0045; beta_{eur}=-0.0464, p_{eur}=0.0112) than in the full set of individuals. These associations attenuated but were not completely diminished when 329 330 evaluating participants who were not diagnosed with CAD. Next, given the longitudinal 331 nature of availability of comorbidities in the EHR, we aimed to measure the impact of risk of 332 CAD on the first reported incidence of CAD and breast cancer in females. The overlap on individuals who were diagnosed with CAD and breast cancer in our study population 333 334 suggests that females with a diagnosis of CAD are less likely to be diagnosed or report a 335 history of breast cancer (Figure 2C).

336

337 Mendelian Randomization

We performed one-sample MR in PMBB and eMERGE for the 29 associations that 338 339 were FDR-significant and combined them through a meta-analysis (Figure 3A). The majority 340 of analyses were significant (p < 0.05), and the direction of the estimated beta coefficient for 341 each association aligned with the direction of effect seen in the PRS association analysis. Our 342 results support a potential causal relationship between many cardiometabolic phenotypes and 343 female health conditions, with the most significant associations being between T2D and gestational diabetes (All: p=1.5x10⁻¹¹, beta=1.52, se=0.23; EUR: p=2.4x10⁻¹⁰, beta=1.78, 344 345 se=0.28) and BMI and PCOS (All: p=1.1x10⁻⁸, beta=0.0021, se=0.00037; EUR: p=3.6x10⁻⁸, 346 beta=0.0021, se=0.0038).

We also performed two-sample MR to leverage the power of larger GWAS for our female health conditions (Figure 3B). Most analyses were significant when using the IVW method but became less significant when using the MR Egger and the weighted median methods. Some associations remained significant for all three methods, particularly CAD with breast cancer (IVW: beta=-0.0587, se=0.021, p=0.00463; MR Egger: beta=-0.102,

se=0.049, p=0.04; Weighted median: beta=-0.0642, se=0.028, p=0.021) and T2D and
gestational diabetes (IVW: beta=0.613, se=0.044, p=1.73x10⁻⁴³; MR Egger: beta=0.656,
se=0.11, p=8.8x10⁻¹⁰; Weighted median: beta=0.635, se=0.066, p=8.12x10⁻²²).

355

356 Investigation of the role of population stratification

357 Population stratification could have confounded our results in the PRS association and the MR analyses. Therefore, we tested the association of the PRS with the PCs 358 (Supplementary Table 3). The high R^2 for most cardiometabolic PRS shows that a large 359 360 amount of the variance in the PRS could be explained by the PCs when considering all multi-361 ancestry variables, and the R² decreases when analyzing only European or African ancestry 362 groups. The PCs explained more of the variance in PRS for African ancestry individuals than 363 European ancestry individuals, a finding that suggests there is more population stratification 364 among our African ancestry individuals and that there could be confounding factors 365 influencing some results. To overcome these biases, we accounted for PCs in both our PRS association analyses and the one-sample MR analyses. Additionally, we ran one-sample MR 366 367 without adjusting for the covariates (PCs and birth year) and compared the results with the adjusted ones (Supplementary Table 4). 368

369

370 Chronology analyses

EHR is a powerful resource to visualize the landscape of events in a patient's diagnosis. Continuing on the theme of genetic correlation and the influence of shared genetic burden of cross-trait analyses, we investigated if an individual's genetic burden for cardiometabolic diseases may also affect the time at which they develop certain female health conditions. Case prevalence for female health conditions was generally higher in the high PRS group in the younger age groups (Figure 4 and Supplementary Figures 18-22). Many

377 pregnancy-related phenotypes were most prevalent in the 25-40 years age group, but for 378 participants who developed those phenotypes in the <25 years age group, the relative 379 difference in prevalence between the high-risk and low-risk PRS group was larger. The 380 cardiometabolic PRS used to define high-risk and low-risk groups did not seem to affect case 381 prevalence for most phenotypes, but phenotypes found to be associated with specific 382 cardiometabolic PRS in the association analysis did show differences across PRS. Gestational 383 hypertension and preeclampsia were generally more prevalent in the younger age groups (<25 384 and 25-40) for participants with high blood pressure PRS than for participants with high PRS 385 for other phenotypes. Similar trends were observed for other traits, such as the PRS_{T2D} with 386 gestational diabetes and the PRS_{BMI} with PCOS. High prevalence of endometriosis and 387 uterine fibroid cases were also observed in individuals with high-risk PRS, particularly in the 388 age group 25-40.

389 Discussion:

390 We have demonstrated high genetic correlation and shared genetic burden between 391 cardiometabolic traits and female health conditions spanning across many obstetrics and 392 gynecological disorders. Additionally, this study shows that genome-wide PRS of 393 cardiometabolic traits has potential translational effects in health conditions unique to 394 females. Initially, we calculated the genetic correlation between phenotypes related to 395 cardiometabolic diseases and traits with female health conditions. Genetic correlation 396 analyses suggested a high overlap among the shared genetic etiology of all phenotypes tested 397 in this study. We further investigated the effect of this shared genetic burden by generating 398 PRS for cardiometabolic phenotypes and testing their association to various female-specific 399 disease conditions. PRS was generally predictive of the primary phenotype, and we identified 400 several FDR-significant associations with female health conditions that were statistically

401 significant after meta-analyzing both datasets. Prior research has established relationships 402 (mainly non-genetic factors) between many of these associations, such as BMI with PCOS 403 and T2D with gestational diabetes^{17,18}. Epidemiological studies have also shown evidence 404 that people with obesity are at high risk for endometrial cancer⁴¹. The associations identified 405 in this study between female health conditions and cardiometabolic PRS suggest genetic basis 406 for these cross-trait categories. In addition, we performed Mendelian randomization and 407 identified potential causal relationships.

408 Unexpectedly, all of our analyses showed that the PRS_{CAD} was inversely associated 409 with breast cancer in European ancestry participants. CAD and breast cancer share many 410 common risk factors, such as smoking and diet⁴². However, our results suggest that a high 411 genetic burden for CAD is protective for breast cancer. Participants in our cohorts with high 412 PRS_{CAD} had lower incidence of breast cancer. When we evaluated the individuals with high 413 PRS_{CAD} but no CAD diagnoses, we still saw a moderate but decreased risk for breast cancer. 414 Several factors might contribute to these associations. First, these patterns might reflect 415 ascertainment biases and competing risks. Individuals with higher risk of CAD likely live 416 shorter lives and thus are not diagnosed with breast cancer. Second, the treatments and drugs given for treating CAD might also protect against breast cancer. Lastly, genetic mechanisms 417 predisposing individuals to CAD might show protective effects for breast cancer. Briefly, 418 419 among the SNPs that passed genome-wide significance in the CAD GWAS we used to 420 calculate the PRS_{CAD}, 125/220 SNPs had opposite directions of effects in the breast cancer GWAS we used in the two-sample MR. For example, rs1011970 (CAD: beta=-0.0407, 421 p=6.94x10⁻¹⁰; breast cancer: beta=0.053, p= $3.1x10^{-5}$) is a known risk variant for both CAD 422 423 and breast cancer and maps to the CDKN2B-AS1 gene, which helps silence genes 424 epigenetically in the CDKN2A-CDKN2B cluster⁴³. CDKN2B-AS1 knockdown suppresses 425 breast cancer progression, and decreased expression of CDKN2B increases development of

426 atherosclerotic plaques⁴⁴⁻⁴⁶. Variants that promote decreased *CDKN2B-AS1* expression could 427 increase breast cancer risk but increase expression of *CDKN2B* and subsequently decrease 428 CAD risk. A recent study also shows this protective effect of a PRS_{CAD} on breast cancer, and 429 more research should be undertaken to uncover the mechanisms behind this association⁴⁷.

430 The differences between the three PRS_{blood pressure} suggests that analyzing the genetic 431 burden for all three blood pressure traits might elucidate the understanding of hypertension during pregnancy. Only the PRS_{SBP} was significantly associated with gestational 432 433 hypertension and preeclampsia in African ancestry individuals. Prior studies have identified 434 variability in the predictive performance when using different blood pressure measurements 435 to predict hypertension and other diseases, and our results warrant further studies to replicate 436 this association in other large multi-ancestry datasets to reach a more definite conclusion on 437 the role blood pressure measurements play in predicting hypertensive diseases during pregnancy 48,49 . 438

439 To further investigate the effect of cardiometabolic genetic burden on conditions 440 unique to females, we drew information from EHRs to capture the landscape of trajectories of 441 diseases presented at different ages. We found that a high genetic burden for most 442 cardiometabolic phenotypes could increase risk of developing female health conditions at 443 earlier ages, even if there was no overall association between the PRS and the condition. For 444 example, the PRS_{BMI} was not associated with many pregnancy-related complications such as 445 gestational hypertension and ectopic pregnancy. However, in the youngest age group (<25), 446 these phenotypes were more prevalent in the high PRS_{BMI} group than the low PRS_{BMI} group. 447 Similarly, there was no association overall between the PRS_{SBP} and PCOS or endometriosis, 448 but participants who developed PCOS before 25 years old or endometriosis between 25-40 449 years old were more likely to have high PRS. The difference in case prevalence between high 450 and low PRS groups for these phenotypes decreased in older age groups. Patients with high

451 genetic burden for cardiometabolic phenotypes could be at higher risk to develop female 452 health conditions at younger ages. These findings can be particularly of importance to 453 prioritize patients for early screening.

The limitations of our study point to many promising future directions. First, our 454 455 study establishes a link between the genetic burden for different cardiometabolic phenotypes 456 and several diseases unique to females. However, we estimate the genetic burden by using 457 PRS alone, which are calculated based on common variants and do not include the effects of 458 other genetic risk factors such as rare variants and copy number variations. Second, our 459 analysis does not consider clinical or environmental factors that could influence the 460 associations between cardiometabolic and female health conditions. We found that 461 population stratification is potentially present in our datasets and accounted PCs in our 462 analyses accordingly. However, important social and environmental risk factors such as 463 education level and socioeconomic status were missing and could not be properly accounted 464 for in our current analyses. Our focus on PRS alone reflects the current limitations of 465 methods for multi-modal risk model predictions. Current widespread interest in building integrative risk models suggests that this gap can be closed in the near future^{27,50}. 466 Furthermore, the weaker performance of PRS in African ancestry individuals contributed to 467 the lack of power to identify African ancestry specific associations and suggests the urgent 468 469 need for expanding studies to include more racially and ethnically diverse cohorts.

The low sample size for some conditions may have limited the power of our onesample MR analyses. In addition, while our two-sample MR uses GWAS from larger cohorts, they were performed on populations of primarily European ancestry and thus lack the power to detect causality for the non-European ancestry participants in our cohort. The effects we see in our MR results may be biased due to horizontal pleiotropy, in which genetic variants associated with the exposure (cardiometabolic phenotypes) affect other traits that

subsequently influence the outcome (female health conditions). The effects of pleiotropy can be seen from the decreased statistical significance when using the weighted median and MR Egger methods in the two-sample MR. For example, the relationship between T2D and PCOS became insignificant when using the MR Egger method (p = 0.109) compared to the IVW method (p = 0.000148). These methods account for pleiotropy and other confounding factors but may not have captured all their effects.

482 EHRs are particularly advantageous in investigating disease trajectories and 483 progression. Our analyses in this study provided a big picture visualization of the burden of 484 early diagnoses of disease unique to females at early ages among the high cardiometabolic 485 PRS group. However, these analyses might point to the ascertainment biases of EHR and 486 including confounding factors for statistically informed findings. This study illustrates the 487 influence of cardiometabolic genetic burden on diverse phenotypes. Our findings serve as the 488 initial basis for presenting the clinical utility of cardiometabolic PRS as non-modifiable risk 489 factors for screening and early diagnostic tools for a variety of obstetric and gynecological 490 conditions. To improve the power of cardiometabolic PRS for predicting risk for female 491 health conditions and better understand the relationship between these phenotypes, future 492 studies should incorporate PRS with other genetic and non-genetic risk factors and study their 493 effects on larger and more diverse multi-ancestry populations.

495 Acknowledgements: We acknowledge the Penn Medicine BioBank (PMBB) for 496 providing data and thank the patient-participants of Penn Medicine who consented to 497 participate in this research program. We would also like to thank the Penn Medicine BioBank 498 team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol #813913 and supported by Perelman School of 499 500 Medicine at University of Pennsylvania. Approval for PMBB was given from the University 501 of Pennsylvania Institutional Review Board. The PMBB study has been determined to pose 502 minimal risk to subjects.

503

504 **Sources of Funding:** The eMERGE Network was initiated and funded by NHGRI 505 through the following grants:

506 Phase IV: U01HG011172 (Cincinnati Children's Hospital Medical Center); U01HG011175 507 (Children's Hospital of Philadelphia); U01HG008680 (Columbia University); U01HG011176 508 (Icahn School of Medicine at Mount Sinai); U01HG008685 (Mass General Brigham); 509 U01HG006379 (Mayo Clinic); U01HG011169 (Northwestern University); U01HG011167 510 (University of Alabama at Birmingham); U01HG008657 (University of Washington Medical 511 Center, Seattle); U01HG011181 (Vanderbilt University Medical Center); U01HG011166 512 (Vanderbilt University Medical Center serving as the Coordinating Center) 513 Phase III: U01HG8657 (Kaiser Permanente Washingtom/University of Washington Medical 514 Center); U01HG8685 (Brigham and Women's Hospital); U01HG8672 (Vanderbilt University 515 Medical Center); U01HG8666 (Cincinnati Children's Hospital Medical Center); U01HG6379 516 (Mayo Clinic); U01HG8679 (Geisinger Clinic); U01HG8680 (Columbia University Health 517 Sciences); U01HG8684 (Children's Hospital of Philadelphia); U01HG8673 (Northwestern 518 University); U01HG8701 (Vanderbilt University Medical Center serving as the Coordinating 519 Center); U01HG8676 (Partners Healthcare/Broad Institute); and U01HG8664 (Baylor 520 College of Medicine).

- 521
- 522 **Disclosures:** None

523 **References:**

- 524 1. Chang C, Zhang K, Veluchamy A, et al. A Genome-Wide Association Study Provides
- 525 New Evidence That CACNA1C Gene is Associated With Diabetic Cataract. *Invest*
- 526 *Ophthalmol Vis Sci.* 2016;57(4):2246-2250.
- 527 2. Patel SR. Shared genetic risk factors for obstructive sleep apnea and obesity. J Appl
- 528 *Physiol* (1985). 2005;99(4):1600-1606.

- 3. Zhuang QS, Zheng H, Gu XD, Shen L, Ji HF. Detecting the genetic link between
 Alzheimer's disease and obesity using bioinformatics analysis of GWAS
 data. *Oncotarget*. 2017;8(34):55915-55919.
- 4. Rashkin SR, Graff RE, Kachuri L, et al. Pan-cancer study detects genetic risk variants
 and shared genetic basis in two large cohorts. *Nat Commun.* 2020;11(1):4423.
 Published 2020 Sep 4.
- 535 5. Blüher M. Obesity: global epidemiology and pathogenesis. *Nat Rev Endocrinol*.
 536 2019;15(5):288-298.
- 537 6. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence
 538 estimates for 2019 and projections for 2030 and 2045: Results from the International
 539 Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract.*540 2019;157:107843.
- 7. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and 541 542 national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease 543 544 Study 2015 [published correction Lancet. 2017 appears in Jan 7;389(10064):e1]. Lancet. 2016;388(10053):1459-1544. 545
- 8. Buddeke J, Bots ML, van Dis I, et al. Comorbidity in patients with cardiovascular
 disease in primary care: a cohort study with routine healthcare data. *Br J Gen Pract*.
 2019;69(683):e398-e406.
- 549 9. Kendir C, van den Akker M, Vos R, Metsemakers J. Cardiovascular disease patients
 550 have increased risk for comorbidity: A cross-sectional study in the Netherlands. *Eur J*551 *Gen Pract.* 2018;24(1):45-50.
- 552 10. Kulie T, Slattengren A, Redmer J, Counts H, Eglash A, Schrager S. Obesity and
 553 women's health: an evidence-based review. *J Am Board Fam Med*. 2011;24(1):75-85.

- 554 11. Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ. Preeclampsia: Risk Factors,
- 555 Diagnosis, Management, and the Cardiovascular Impact on the Offspring. *J Clin Med*.
 556 2019;8(10):1625. Published 2019 Oct 4.
- 557 12. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO
 558 systematic analysis. *Lancet Glob Health*. 2014;2(6):e323-e333.
- 13. Baharuddin M, Amelia D, Suhowatsky S, Kusuma A, Suhargono MH, Eng B.
 Maternal death reviews: A retrospective case series of 90 hospital-based maternal
 deaths in 11 hospitals in Indonesia. *Int J Gynaecol Obstet*. 2019;144 Suppl 1:59-64.
- 562 14. Gerdts E, Regitz-Zagrosek V. Sex differences in cardiometabolic disorders. *Nat Med.*563 2019;25(11):1657-1666.
- 564 15. Garovic VD, August P. Preeclampsia and the future risk of hypertension: the pregnant
 565 evidence. *Curr Hypertens Rep.* 2013;15(2):114-121.
- 566 16. Tooher J, Thornton C, Makris A, Ogle R, Korda A, Hennessy A. All Hypertensive
 567 Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease.
 568 *Hypertension*. 2017 Oct;70(4):798-803.
- 569 17. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the 570 polycystic ovary syndrome. *Int J Obes Relat Metab Disord*. 2002;26(7):883-896.
- 571 18. Kwak SH, Jang HC, Park KS. Finding genetic risk factors of gestational
 572 diabetes. *Genomics Inform*. 2012;10(4):239-243.
- 573 19. Gambineri A, Patton L, Altieri P, et al. Polycystic ovary syndrome is a risk factor for
 574 type 2 diabetes: results from a long-term prospective study. *Diabetes*.
 575 2012;61(9):2369-2374. doi:10.2337/db11-1360
- 576 20. Mu F, Rich-Edwards J, Rimm EB, Spiegelman D, Missmer SA. Endometriosis and
 577 Risk of Coronary Heart Disease. *Circ Cardiovasc Qual Outcomes*. 2016;9(3):257578 264.

- 579 21. Dawson A, Fernandez ML, Anglesio M, Yong PJ, Carey MS. Endometriosis and
- 580 endometriosis-associated cancers: new insights into the molecular mechanisms of
- 581 ovarian cancer development. *Ecancermedicalscience*. 2018;12:803.
- 582 22. Paul A, Paul S. The breast cancer susceptibility genes (BRCA) in breast and ovarian
 583 cancers. *Front Biosci (Landmark Ed)*. 2014;19:605-618.
- 584 23. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic
 585 and environmental effects for pre-eclampsia and gestational hypertension: a family
 586 study. *BJOG*. 2004;111(3):200-206.
- 587 24. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary
 588 syndrome in a Dutch twin-family study. *J Clin Endocrinol Metab*. 2006;91(6):2100589 2104. doi:10.1210/jc.2005-1494
- 590 25. Vujkovic M, Keaton JM, Lynch JA, et al. Discovery of 318 new risk loci for type 2
 591 diabetes and related vascular outcomes among 1.4 million participants in a multi592 ancestry meta-analysis. *Nat Genet.* 2020;52(7):680-691.
- 593 26. Justice AE, Winkler TW, Feitosa MF, et al. Genome-wide meta-analysis of 241,258
 594 adults accounting for smoking behaviour identifies novel loci for obesity traits. *Nat*595 *Commun.* 2017;8:14977.
- 596 27. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical
 597 instruments. *Genome Med.* 2020;12(1):44. Published 2020 May 18.
- 598 28. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for
 599 common diseases identify individuals with risk equivalent to monogenic
 600 mutations. *Nat Genet*. 2018;50(9):1219-1224.
- Steinthorsdottir V, McGinnis R, Williams NO, et al. Genetic predisposition to
 hypertension is associated with preeclampsia in European and Central Asian women.
 Nat Commun. 2020;11(1):5976.

- 30. Verma A, Ritchie MD. Current Scope and Challenges in Phenome-Wide Association
 Studies. *Curr Epidemiol Rep.* 2017;4(4):321-329.
- 606 31. Fritsche LG, Gruber SB, Wu Z, et al. Association of Polygenic Risk Scores for
 607 Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics
 608 Initiative. *Am J Hum Genet*. 2018;102(6):1048-1061.
- 32. Shen X, Howard DM, Adams MJ, et al. A phenome-wide association and Mendelian
 Randomisation study of polygenic risk for depression in UK Biobank. *Nat Commun.*2020;11(1):2301.
- 612 33. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
- 613 PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4:7.
- 614 34. Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression distinguishes
 615 confounding from polygenicity in genome-wide association studies. *Nat Genet*.
 616 2015;47(3):291-295.
- 617 35. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of
 618 current polygenic risk scores may exacerbate health disparities. *Nat Genet*.
 619 2019;51(4):584-591.
- 620 36. Duncan L, Shen H, Gelaye B, et al. Analysis of polygenic risk score usage and
 621 performance in diverse human populations. *Nat Commun.* 2019;10(1):3328.
- 622 37. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *Journal*623 *of Statistical Software*. 2010;36(3):1-48.
- 624 38. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian
 625 regression and continuous shrinkage priors. *Nat Commun.* 2019;10(1):1776.
- 626 39. Pendergrass SA, Dudek SM, Crawford DC, Ritchie MD. Visually integrating and
 627 exploring high throughput Phenome-Wide Association Study (PheWAS) results using
 628 PheWAS-View. *BioData Min.* 2012;5(1):5.

- 40. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic
 causal inference across the human phenome. *Elife*. 2018;7:e34408.
- 41. Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial
 Cancer Risk, Prevention, and Treatment. *J Clin Oncol.* 2016;34(35):4225-4230.
- 42. Mehta LS, Watson KE, Barac A, et al. Cardiovascular Disease and Breast Cancer:
 Where These Entities Intersect: A Scientific Statement From the American Heart
 Association [published correction appears in Circulation. 2019 Aug
 27;140(9):e543]. *Circulation*. 2018;137(8):e30-e66.
- 43. Huang K, Zhong J, Li Q, et al. Effects of CDKN2B-AS1 polymorphisms on the
 susceptibility to coronary heart disease. *Mol Genet Genomic Med*. 2019;7(11):e955.
- 44. Qin S, Ning M, Liu Q, Ding X, Wang Y, Liu Q. Knockdown of long non-coding
 RNA CDKN2B-AS1 suppresses the progression of breast cancer by miR-1225p/STK39 axis. *Bioengineered*. 2021;12(1):5125-5137.
- 642 45. Kojima Y, Downing K, Kundu R, et al. Cyclin-dependent kinase inhibitor 2B
 643 regulates efferocytosis and atherosclerosis. *J Clin Invest.* 2014;124(3):1083-1097.
- 644 46. Motterle A, Pu X, Wood H, et al. Functional analyses of coronary artery disease
 645 associated variation on chromosome 9p21 in vascular smooth muscle cells. *Hum Mol*646 *Genet.* 2012;21(18):4021-4029.
- 647 47. Clark SL, Parham M, Shadyab AH, et al. Broad Clinical Manifestations of Polygenic
 648 Risk for Coronary Artery Disease in the Women's Health Initiative. medRxiv
 649 2021.06.15.21258993
- 48. Kanegae H, Oikawa T, Okawara Y, Hoshide S, Kario K. Which blood pressure
 measurement, systolic or diastolic, better predicts future hypertension in normotensive
 young adults?. *J Clin Hypertens (Greenwich)*. 2017;19(6):603-610.

- 49. Sesso HD, Stampfer MJ, Rosner B, et al. Systolic and diastolic blood pressure, pulse
 pressure, and mean arterial pressure as predictors of cardiovascular disease risk in
 Men. *Hypertension*. 2000;36(5):801-807.
- 50. Kachuri L, Graff RE, Smith-Byrne K, et al. Pan-cancer analysis demonstrates that
 integrating polygenic risk scores with modifiable risk factors improves risk
 prediction. *Nat Commun.* 2020;11(1):6084.

659 Figure Legends:

Figure 1: Genetic correlation and the influence of shared genetic burden of 660 cardiometabolic traits and health conditions unique to females. Panel A shows a heatmap 661 of genetic correlation from cross-trait LDSC analyses: Blue represents negative correlation 662 and red represents positive correlation. An * in each box suggests statistical significance of 663 664 results based on p-values. Panels B, C and D refer to PRS based meta-analyses between 665 cardiometabolic PRS and case/controls status of female-specific diseases in overall, EUR and 666 AFR ancestry individuals respectively. The first panel in these plots corresponds to p-values 667 and second panel represents beta estimates. The color of each point refers to the PRS for 668 cardiometabolic traits.

669

670 Figure 2: Inverse relationship between Coronary Artery Disease (CAD) and Breast

671 **Cancer.** Panel A shows the heatmap of negative genetic correlation between CAD and breast

672 cancer from the UKBB Genetic Correlation Browser dataset. The gradient of color refers to

673 positive (red) to negative (blue) correlation, and the text in each box refers to the genetic

- 674 correlation coefficient. Panel B shows the distribution of breast cancer per each PRS_{CAD}
- quintile. The x-axis represents each PRS quintile, and the y-axis is the disease prevalence.
- 676 The color of each point refers to the ancestry group (All, European, and African), and the

shape indicates the target dataset (eMERGE (circle) or PMBB (triangle)). Panel C is a Venn
diagram representing the overlap of CAD and breast cancer cases in PMBB and eMERGE
datasets based on disease diagnosis.

680

Figure 3: Mendelian Randomization (MR) results for 29 significant PRS based 681 682 associations. This figure shows forest plots of association between female health conditions as outcomes and cardiometabolic phenotypes as exposures in a one-sample MR analyses 683 684 shown in Panel A and two-sample MR analyses shown in Panel B. Genetic instruments are 685 the cardiometabolic PRS in the one-sample MR and genome-wide significant SNPs from 686 GWAS in the two-sample MR. In panel A, each point refers to beta outcome/SD exposure for 687 PRS_{BMI} and log(OR) outcome for all other exposure variables for each tests performed as 688 separated by ancestry. In panel B, each point refers to beta outcome/SD exposure for BMI 689 and beta outcome/SD log(OR) exposure for all other variables across all methods used in 690 sensitivity analyses for two-sample MR. P-values are reported in last column in both panels. 691

692 Figure 4: Chronology analyses for the visualization of events from the EHR. Circular

plot showing disease prevalence among high PRS_{BMI} (in yellow) and low PRS_{BMI} (in blue) categories. General female health conditions are shown in panel A and pregnancy and childbirth-related phenotypes are shown in panel B. The circular plots are divided into five age categories (<25, 25-40, 40-55, 55-70, and >70) for general female health conditions and three age categories (<25, 25-40, and 40-55) for pregnancy-related phenotypes

Tables:

Table 1: Sample size in PMBB and eMERGE datasets, for overall and stratified by ancestry analyses.

Phenotype	PMBB Sampl (N Cases)	le Size		eMERGE Sat (N Cases)	eMERGE Sample Size (N Cases)				
	All	EUR	AFR	All	EUR	AFR			
Cardiometabolic Phenotypes									
BMI	20,209	12,344	6,744	39,403	31,875	5,250			
CAD	21,837 (3,002)	13,515 (1,956)	7,039 (955)	49,171 (9,597)	37,003 (7,524)	8,308 (1,308)			
DBP	21,612	13,343	6,994	NA	NA	NA			
Hypertension	21,837 (10,278)	13,515 (5,640)	7,039 (4,286)	49,171 (27,685)	37,003 (20,820)	8,308 (4,695)			
T2D	21,837 (4,388)	13,515 (1,969)	7,039 (2,221)	49,171 (12,403)	37,003 (8,311)	8,308 (2,725)			
Women's Health Phenot	vpes								
Breast cancer	21,837 (1,621)	13,515 (1,621)	7,039 (415)	49,171 (4,148)	37,003 (3,532)	8,308 (408)			

Cervical cancer	21,837	13,515	7,039	49,171	37,003	8,308
	(105	(53)	(50)	(332)	(252)	(52)
Ectopic	2,808	1,201	1,319	3,078	1,975	641
pregnancy	(1,779)	(827)	(757)	(332)	(521)	(153)
Endometrial cancer	21,837	13,515	7,039	49,171	37,003	8,308
	(286)	(183)	(90)	(771)	(653)	(74)
Endometriosis	21,837	13,515	7,039	49,171	37,003	8,308
	(701)	(320)	(340)	(2,314)	(1,805)	(330)
Excessive fetal growth	693	293	329	2,433	1,618	437
	(85)	(37)	(42)	(627)	(377)	(150)
Gestational	2,655	1,111	1,262	3,174	2,005	719
diabetes	(523)	(193)	(248)	(762)	(414)	(244)
Gestational	2,666	1,118	1,275	3,135	1,980	711 (235)
hypertension	(631)	(256)	(324)	(703)	(383)	
Intrauterine	685	289	324	2,156	1,438	358
death	(57)	(23)	(27)	(64)	(38)	(17)
Miscarriage	2,934	1,273	1,360	3,568	2,323	740
	(389)	(199)	(151)	(823)	(547)	(182)
Ovarian cancer	21,837	13,515	7,039	49,171	37,003	8,308
	(305)	(191)	(89)	(1,589)	(1,324)	(177)

Placenta	1,192	482	586	2,674	1,697	583
abruption/previa	(396)	(157)	(195)	(997)	(616)	(240)
Polycystic ovarian syndrome	21,837 (736)	13,515 (387)	7,039 (272)	49,171 (1,006)	37,003 (690)	8,308 (200)
Poor fetal	792	325	388	2,209	1,478	360
growth	(202)	(78)	(107)	(167)	(102)	(21)
Postpartum	924	374	466	2,417	1,579	457
depression	(384)	(136)	(226)	(555)	(319)	(157)
Postpartum	846	350	408	2,320	1,544	408
hemorrhage	(283)	(108)	(146)	(401)	(250)	(104)
Preeclampsia	2,631	1,100	1,264	3,132	1,974	713
	(452)	(149)	(272)	(702)	(377)	(13)
Preterm birth	687	284	332	2,144	1,433	350
	(66)	(21)	(40)	(57)	(30)	(13)
Stillbirth	649	270	311	2,123	1,417	347
	(17)	(3)	(12)	(8)	(6)	(0)
Uterine cancer	21,837	13,515	7,039	49,171	37,003	8,308
	(113)	(66)	(43)	(418)	(340)	(58)
Uterine fibroid	21,837	13,515	7,039	49,171	37,003	8,308
	(1,570)	(516)	(984)	(5,711)	(3,912)	(1,347)

Vaginal cancer	21,837	13,515	7,039	49,171	37,003	8,308
	(23)	(13)	(9)	(109)	(86)	(17)
Vulvar cancer	21,837	13,515	7,039	49,171	37,003	8,308
	(41)	(25)	(14)	(120)	(92)	(19)

Table 2: GWAS summary statistics datasets that are used for the calculation of genetic correlations and polygenic risk scores and the number of

 SNPs used from each GWAS to calculate the corresponding PRS.

Phenotype	Ancestries Included	Source	SampleSize(NumberofCases)	N SNPs included in PRS
Type 2 Diabetes	EUR, AFR, EAS, SAS, HIS	Vujkovic et al., Nat Gen, 2020, MVP	1,407,282 (228,499)	PMBB: 1,023,697 eMERGE: 716,330
Body Mass Index	EUR, AFR, EAS, SAS, HIS	Justice et al., Nat Com, 2017, GIANT	241,258	PMBB: 885,143 eMERGE: 614,668

Hypertension SBP, PP)	(DBP,	EUR, AFR, EAS, SAS, HIS	Giri et al., Nat Gen, 2019, MVP	318,891	PMBB: 1,024,567 eMERGE: 715,471
Coronary Disease	Artery	EUR, EAS, SAS, HIS, AFR	van der Harst et al., Circ Res, 2018, CARDIoGRAMplusC4D + UKBB	547,261 (122,733)	PMBB: 981,480 eMERGE: 681,029

**DBP= Diastolic Blood Pressure; SBP= Systolic Blood Pressure; PP= Pulse Pressure; EUR= European ancestry; EAS= East Asian ancestry; SAS= South Asian ancestry; HIS= Hispanic ancestry; AFR= African ancestry; MVP= Million Veterans Program; GIANT=The Genetic Investigation of ANthropometric Traits; UKB= UK BioBank

Phenotype	Ancestry	N Total	N Cases	R ² or AUC of Full Model	Beta	SE	P-value	R ² or AUC of Null Model	R ² or AUC of PRS only Model
eMERGE				·	·			·	
BMI	All	39,403		0.08494	2.378	0.05044	0	0.0334	0.0593
	EUR	31,875		0.07208	2.336	0.05144	0	0.0121	0.0583
	AFR	5,250		0.07424	2.76	0.25	5.01E-28	0.0529	0.0201
CAD	All	49,171	9,597	0.784	0.3091	0.01318	1.62E-121	0.7745	0.5474
	EUR	37,003	7,524	0.7722	0.3096	0.01427	2.82E-104	0.7608	0.5614
	AFR	8,308	1,308	0.8299	0.308	0.04789	1.24E-10	0.827	0.5442
DBP (Hypertension)	All	49,171	27,685	0.8109	0.1387	0.01347	7.17E-25	0.8099	0.529
	EUR	37,003	20,820	0.7961	0.1464	0.01487	7.02E-23	0.7946	0.5339
	AFR	8,308	4,695	0.8634	0.1503	0.04098	0.000245	0.8628	0.5114
PP (Hypertension)	All	49,171	27,685	0.8115	0.1644	0.01344	2.15E-34	0.8099	0.526
	EUR	37,003	20,820	0.7969	0.1712	0.01438	1.13E-32	0.7946	0.5273
	AFR	8,308	4,695	0.8629	0.09689	0.04871	0.0467	0.8628	0.5049
SBP (Hypertension)	All	49,171	27,685	0.8131	0.2977	0.01665	1.86E-71	0.8099	0.5352
	EUR	37,003	20,820	0.7992	0.3156	0.01793	2.28E-69	0.7946	0.5428
	AFR	8,308	4,695	0.8637	0.2845	0.06227	4.91E-06	0.8628	0.5116
T2D	All	49,171	12,403	0.7193	0.6334	0.01914	3.02E-240	0.691	0.6163
	EUR	37,003	8,311	0.6869	0.6311	0.0205	3.56E-208	0.6414	0.6033
	AFR	8,308	2,725	0.7795	0.6318	0.06546	4.83E-22	0.7728	0.5597
PMBB	ı	I	I	I		I	1	1	1

Table 3: Effect estimates for testing association of PRS with its primary phenotype in eMERGE and PMBB datasets

BMI	All	20,209		0.1542	2.658	0.08244	2.05E-222	0.1108	0.1417
	EUR	12,344		0.07473	2.621	0.08679	2.66E-193	0.006422	0.06782
	AFR	6,744		0.03203	2.708	0.2089	5.75E-38	0.008037	0.02711
CAD	All	21,837	3,002	0.8235	0.3571	0.02354	5.73E-52	0.8148	0.5619
	EUR	13,515	1,956	0.8303	0.3894	0.02732	4.44E-46	0.8185	0.5929
	AFR	7,039	955	0.799	0.2566	0.05214	8.60E-07	0.7955	0.5389
DBP	All	21,612		0.0425	1.036	0.06661	3.05E-54	0.03183	0.02905
	EUR	13,343		0.01534	0.9964	0.08064	7.01E-35	0.004144	0.01213
	AFR	6,994		0.04559	1.104	0.129	1.35E-17	0.03571	0.01375
PP (Hypertension)	All	21,837	10,278	0.8125	0.1942	0.02328	7.18E-17	0.8112	0.602
	EUR	13,515	5,640	0.7797	0.1918	0.02638	3.53E-13	0.7778	0.5272
	AFR	7,039	4,286	0.8389	0.1886	0.05376	0.00045	0.8383	0.5391
SBP (Hypertension)	All	21,837	10,278	0.8144	0.327	0.02523	2.08E-38	0.8112	0.6097
	EUR	13,515	5,640	0.7813	0.279	0.02846	1.11E-22	0.7778	0.5397
	AFR	7,039	4,286	0.8415	0.4505	0.05923	2.81E-14	0.8383	0.5649
T2D	All	21,837	4,388	0.754	0.8136	0.03523	5.49E-118	0.7287	0.6713
	EUR	13,515	1,969	0.712	0.8418	0.04533	5.55E-77	0.6634	0.6323
	AFR	7,039	2,221	0.7342	0.7896	0.05947	3.11E-40	0.7168	0.5919

**BMI= Body Mass Index; CAD= Coronoray artery disease, T2D=Type 2 Diabetes; DBP= Diastolic Blood Pressure; SBP= Systolic Blood

Pressure; PP= Pulse Pressure; EUR= European ancestry; AFR= African ancestry; Beta coefficients and standard errors are per SD PRS in the full model. Covariates included: birth year and the first five PCs.

Table 4: FDR-significant (FDR P-value < 0.05) associations between cardiometabolic PRS and female health conditions identified in the PMBB</th>

 and eMERGE meta-analysis


PRS	Association	Ancestry	Beta	SE	OR	95% CI	P-value
BMI	Breast cancer	All	-0.071	0.0225	0.93	0.891-0.973	0.00159
	Endometrial cancer	All	0.244	0.0458	1.28	1.17-1.4	9.4x10 ⁻⁸
		EUR	0.276	0.087	1.32	1.11-1.56	0.00152
Gestational diabetes	All	0.23	0.0508	1.26	1.14-1.39	6x10 ⁻⁶	
	EUR	0.277	0.0622	1.32	1.17-1.49	8.69x10 ⁻⁶	
	PCOS	All	0.272	0.0387	1.31	1.22-1.42	2.37x10 ⁻¹²
		EUR	0.294	0.0451	1.34	1.23-1.47	6.76x10 ⁻¹¹
CAD	Breast cancer	All	-0.0718	0.0147	0.931	0.904-0.958	9.96x10 ⁻⁷
		EUR	-0.0699	0.0168	0.932	0.902-0.964	3.11x10 ⁻⁵
	Postpartum depression	EUR	0.178	0.0577	1.19	1.07-1.34	0.00201
РР	Gestational	All	0.218	0.0443	1.24	1.14-1.36	8.51x10 ⁻⁷
	hypertension	EUR	0.235	0.0558	1.26	1.13-1.41	2.54x10 ⁻⁵
	Preeclampsia	All	0.196	0.0581	1.22	1.09-1.36	0.000762

SBP	Gestational	All	0.332	0.0825	1.39	1.19-1.64	5.61x10 ⁻⁵
	hypertension	EUR	0.306	0.0661	1.36	1.19-1.55	3.61x10 ⁻⁶
		AFR	0.398	0.099	1.49	1.23-1.81	5.7x10 ⁻⁵
SBP	Preeclampsia	All	0.275	0.0799	1.32	1.13-1.54	0.000567
		EUR	0.229	0.0712	1.26	1.09-1.45	0.0013
		AFR	0.358	0.102	1.43	1.17-1.75	0.000517
T2D	Breast cancer	All	-0.0726	0.0213	0.93	0.892-0.97	0.000657
		EUR	-0.0787	0.0263	0.924	0.878-0.973	0.00272
	Gestational diabetes	All	0.587	0.063	1.8	1.59-2.03	1.19x10 ⁻²⁰
		EUR	0.678	0.0759	1.97	1.7-2.29	3.88x10 ⁻¹⁹
	Gestational	All	0.184	0.0642	1.2	1.06-1.36	0.00414
	hypertension	EUR	0.178	0.0671	1.19	1.05-1.36	0.00798
	PCOS	All	0.223	0.0428	1.25	1.15-1.36	1.93x10 ⁻⁷
		EUR	0.209	0.0485	1.23	1.12-1.36	1.56x10 ⁻⁵
		AFR	0.32	0.104	1.38	1.12-1.69	0.00206
	Postpartum depression	All	0.18	0.07	1.2	1.04-1.37	0.0101

**BMI= Body Mass Index; CAD= Coronoray artery disease, T2D=Type 2 Diabetes; PCOS=Polycystic ovarian syndrome; EUR= European ancestry; P= PMBB; E= eMERGE; Beta coefficients are per SD PRS. Results were adjusted for birth year and the first five PCs.

Figures:

Figure 1:








Figure 3:

Α.

Exposure	Outcome Breast Cancer	Ancestry	Р
BMI	Breast Cancer Endometrial Cancer	All -	1.97e-05
	Gestational Diabetes	All EUR	6.25e-07 8.81e-07
	Polycystic Ovarian Syndrome	All - EUR -	0.00152 8.38e-05
	Polycysiic Ovarian Syndrome		1.12e-08 3.63e-08
CAD	Breast Cancer	-0.01 0.0 Beta outcome / S	
OAD		All EUR	3.92e-07 8.8e-06
	Postpartum Depression	EUR 🔶	→ 0.113
HT (PP)	Gestational Hypertension	All	→ 0.000479 0.00972
	Preeclampsia	All -	0.00112
HT (SBP)	Gestational Hypertension	All	0.00559 0.0214 0.0042
T2D	Preeclampsia Breast Cancer	All - EUR - AFR -	6.65e-05 0.0023 0.0052
120	Gestational Diabetes	All : EUR :	0.00026 0.00586
		All - EUR -	- 1.49e-11 - 2.39e-10
	Gestational Hypertension	All EUR -	0.126 0.0363
	Polycystic Ovarian Syndrome	All EUR AFR	3.61e-06 0.00938 0.00278
	Postpartum Depression		
		log(OR) d	outcome

В.

Exposur		Method		P
BMI	Breast Cancer	0.04/		0.00
		IVW	-*	2.26e-10
		MR Egger	-	4.23e-06
	Endometrial Courses	Weighted Median	*	4.18e-10
	Endometrial Cancer	IVW		5.38e-14
		MR Egger		0.0228
		Weighted Median		1.93e-06
	Gestational Diabetes	weighted wedian	87 m	1.936-00
	ocolutional Diabetes	IVW		0.0323
		MR Egger		0.0705
		Weighted Median		0.102
	Polycystic Ovarian Syndrom			0.102
		IVW		4.89e-05
		MR Egger -		0.623
		Weighted Median		0.00119
		с Г	-10123	1
CAD	Breast Cancer			
		IVW		0.00463
		MR Egger	-	0.0402
PP	Gestational Hypertension/ Preeclampsia	Weighted Median	-	0.0205
		IVW		1.97e-05
		MR Egger	-	0.462
		Weighted Median	-	0.0144
SBP	Gestational Hypertension/ Preeclampsia			
	1.5	IVW		3.08e-09
		MR Egger	+	0.0082
		Weighted Median		1.87e-08
T2D	Breast Cancer	5		
		IVW	+	0.981
		MR Egger	+	0.853
		Weighted Median	-	0.409
	Gestational Diabetes	ginteriordian		
		IVW	1 a 3	1.73e-43
		MR Egger		8.8e-10
		Weighted Median	-	8.12e-22
	Gestational Hypertension			
	-	IVW	-	6.96e-05
		MR Egger		0.302
		Weighted Median	-	0.401
	Polycystic Ovarian Syndrom			
		IVW		0.000148
		MR Egger		0.109
		Weighted Median		0.0145
		-01	5 0 0.5 1	

Figure 4:

